Bone anabolic effects of PTH(1 - 34) and salmon calcitonin in ovariectomy- and ovariectomy-steroid-induced osteopenic rats: A histomorphometric and biomechanical study

Japanese Journal of Pharmacology

Volumn 82, Issue 3, 2000, Pages 240-246

  Fukushima, Tohru ^a   Nitta, Takaya ^a   Furuichi, Hiroshi ^a   Izumo, Nobuo ^a   Fukuyama, Tohru ^a   Nakamuta, Hiromichi ^a   Koida, Masao ^a  

^a SETSUNAN UNIVERSITY   (Japan)

Author keywords

Bone anabolic effect; Calcitonin; PTH(1 34); Steroid induced osteopenia

Indexed keywords

ANTIINFLAMMATORY AGENT; METHYLPREDNISOLONE ACETATE; PARATHYROID HORMONE[1-34]; SALCATONIN; STEROID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DENSITY; BONE STRENGTH; CANCELLOUS BONE; CONTROLLED STUDY; CORTICAL BONE; ELASTICITY; FEMALE; METAPHYSIS; NONHUMAN; OSSIFICATION; OSTEOPENIA; OSTEOPOROSIS; OVARIECTOMY; RAT;

EID: 0034115133     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.82.240     Document Type: Article

References (24)

1. Concensus Development Conference: Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 90, 170-210 (1991)
2. Kanis JA, Delmas P, Burckhardt P, Cooper C and Torgerson D: Guidelines for diagnosis and management of osteoporosis. Osteoporosis Int 7, 390-406 (1997)
3. Morley P, Whitfield JF and Willick GE: Anabolic effects of parathyroid hormone on bone. Trends Endocrinol Metab 8, 225-231 (1997)
4. Modey P, Whitfield JF and Willick GE: Parathyroid hormone analogues for treatment of osteoporosis and hypercalcemia. Exp Opin Ther Patents 8, 31-37 (1998)
5. Cosman F and Lindsay R: Is parathyroid hormone a therapeutic option for osteoporosis? A review of the clinical evidence. Calcif Tissue Int 62, 475-480 (1998)
6. Nitta T, Fukushima T, Nakamuta H and Koida M: Glucocorticoid-induced secondary osteopenia in female rats: a time course study as compared with ovariectomy-induced osteopenia and response to salmon calcitonin. Jpn J Pharmacol 79, 379-386 (1999)
7. Nakamuta H, Nitta T, Hoshino T and Koida M: Glucocorticoid-induced osteopenia in rats: histomorphometrical and microarchitectural characterization and calcitonin effect. Biol Pharm Bull 19, 217-219 (1996)
8. Hvin I and Jensen J: Cancellous bone strength at the proximal human tibia. Eng Med 13, 21-25 (1984)
9. Turner CH and Burr DB: Basic biochemical measurements of bone: a tutorial. Bone 14, 595-608 (1993)
10. Liu C-C and Kalu DN: Human parathyroid hormone-(1-34) prevents bone loss and augments bone formation sexually mature ovariectomized rats. J Bone Miner Res 5, 973-982 (1990)
11. Liu C-C, Kalu DN, Salerno E, Echon R, Hollis BW and Ray M: Preexisting bone loss associated with ovariectomy in rats is reversed by parathyroid hormone. J Bone Miner Res 6, 1071-1080 (1991)
12. Søgaard CH, Wronski TJ, McOsker JE and Mosekilde L: The positive effect of parathyroid hormone on femoral neck bone strength in ovariectomized rats is more pronounced than that of estrogen or bisphosphonates. Endocrinology 134, 650-657 (1994)
13. Mosekilde L, Søgaard CH, McOsker JE and Wronski TJ: PTH has a more pronounced effect on vertebral bone mass and biochemical competence than antiresoptive agents (estrogen and bisphosphonate)-assesses in sexually mature, ovariectomized rats. Bone 15, 401-408 (1994)
14. Takahashi N, Udagawa N and Suda T: A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANCL. Biochem Biophys Res Commun 256, 449-455 (1999)
15. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Higashio K and Yamada Y: Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 14, 518-527 (1999)
16. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC and Riggs BL: Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140, 4367-4369 (1999)
17. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC and Khosla S: Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocortocoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140, 4382-4389 (1999)
18. Lee SK and Lorenzo JA: Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 140, 3552-3561 (1999)
19. Selander KS, Harkonen PL, Valve E, Monkkonen J, Hannuniemi R and Vaananen HK: Calcitonin promotes osteoclast survival in vitro. Mol Cell Endocrinol 122, 119-129 (1996)
20. Bronner F and Stein WD: Calcium homeostasis - An old problem revisited. J Nutr 125, 1987S-1995S (1995)
21. Reeva J, Hesp R, Williams D, Hulme P, Klenerman L, Zanelli JM, Darby AJ, Tregear GW and Parsons JA: Anabolic effect of low doses of a fragment of human parathyroid hormone on the sleleton in postmenopausal osteoporosis. Lancet 15, 1035-1038 (1976)
22. Wronski TJ and Yen C-F: Anabolic effects of parathyroid hormone on cortical bone in ovariectomized rats. Bone 15, 51-58 (1994)
23. Baumann BD and Wronski TJ: Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats. Bone 15, 247-253 (1995)
24. Li M and Wronski TJ: Response of femoral neck to estrogen depletion and parathyroid hormone in aged rats. Bone 16, 551-557 (1995)